Cat allergy treatment gets a needle upgrade: fewer shots, same hope

NCT ID NCT06960382

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new method for treating cat allergies called intralymphatic immunotherapy (ILIT), where allergen extracts are injected directly into a lymph node. Thirty-six adults with cat-triggered allergic rhinitis and asthma will receive 3-4 ultrasound-guided injections. The goal is to see if this approach is safe and well-tolerated compared to standard allergy shots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ALUTARD SQ Felis domesticus (cat hair allergen extract)
What this could lead to
If successful, this could lead to a faster, safer way to treat cat allergies with fewer injections than current methods.
What could go wrong
This is an early-phase trial with only 36 participants, so results may not apply to everyone. There is a risk of allergic reactions, including anaphylaxis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Hospital Zurich

    RECRUITING

    Zurich, 8091, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.